Mr. Smith has 30 years of commercial pharmaceutical/biotech industry experience, with deep expertise in rare diseases, particularly pulmonary arterial hypertension (PAH). He currently serves as Chief Commercial Officer at Gossamer Bio. Prior to joining Gossamer, he served in a senior leadership role at Merck & Co. preparing for the launch of sotatercept. He also founded LTM Pharma Consulting, advising pre-commercial rare disease companies on commercial strategy, launch readiness, and organizational development.
Before that, Mr. Smith spent over a decade at Actelion, culminating in his role as Senior Vice President and member of the Executive Leadership Team. He led various commercial functions. During his tenure, he played a pivotal role in the successful launches of the blockbuster PAH therapies OPSUMIT® and UPTRAVI®, contributing to Actelion’s acquisition by Johnson & Johnson.
Earlier in his career, Mr. Smith held commercial leadership positions in marketing, sales, and operations at Nuvelo, Johnson & Johnson, and Bristol-Myers Squibb. He earned a B.B.A. in Marketing from Texas A&M University plus completed executive education at Harvard Business School, The Wharton School, and IMD Business School.